Waiting for a prescription from the ECJ
There is little consistency in the decisions of OHIM's Opposition Division, Boards of Appeal and the Court of First Instance regarding pharmaceutical trade marks. But, say Jean L Pire and Sandra R Paulsson, some guidance is now expected from the European Court of Justice
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
